Cathy Ostos, MD⚕️

Heme/Onc fellow NIH /NCI. Interest #CART #CellularTherapy for solid tumors. Upcoming #GUonc . Loves God ✝️🇻🇦John 1:1-18. Views are my own 🇺🇸 /🇲🇽

[Toni Choueiri, MD @DrChoueiri]

HIGHEST RANKED TRIALS for 2025

TOP 10 #cancerclinicaltrials in 2025 w/MOST Impact

1/ #DeLLphi304 @NEJM led by #Zeusofoncology @g_mountzios @HenryDunantGR : In relapsed SCLC post-platinum, BiTE DLL-3 Tarlatamab improved mOS vs. Chemo (13.6 vs 8.3 m, HR 0.60). PFS and in cancer-related dyspnea also improved.

https://t.co/dlIvlySUT9

[Cathy Ostos, MD⚕️ @ktycat]

Somehow… I’m back. Hello world 🌎

[calliecoombs @calliecoombsmd]

WOW- practice changing MCL trial showing no benefit of autoHCT in uMRD MCL in first remission. Bravo ECOG team. @timfenske #ASH24

[Balazs Halmos @BalazsHalmosMD]

It is a no brainer indeed!
#TumorBoardTuesday
@DrJNaidoo

[Elon Musk @elonmusk]

Not generated by AI

[Samer Al Hadidi, MD,MS,FACP @HadidiSamer]

#ASH24 #mmsm @ASH_hematology

Neurological manifestations of MGUS

[Rafael Fonseca MD 🦔🇺🇸🏜🇲🇽 @Rfonsi1]

Maintenance/consolidation with bispecifics. The talented Dr. Zamagni shows results if SRI. results are nothing but impressive. reminiscent of the data on ALL E1910. This is the way! Look at the MRD rates and PFS
#ASH24RF #MMSM

[Vinay Prasad MD MPH @VPrasadMDMPH]

We got a special guest to join us on stage. Starting in 1 hour. #ash24
Free to all.
A beer after
@AaronGoodman33

[Cathy Ostos, MD⚕️ @ktycat]

Wish I was there 🥲

[Vinay Prasad MD MPH @VPrasadMDMPH]

Coming soon @AaronGoodman33

[Ajay Major, MD, MBA @majorajay]

CAR-T outcomes based on nodal +/- extranodal @gloria_iacoboni #ASH24
- post-CAR OS worse if nodal+EN
- ORR worse with increasing # of EN sites
- sites w/ worse outcomes: bone, liver, GI, renal/adrenal, pancreas
- network analysis reveals connected sites #lymsm #tcellrx

[Emma M. Groarke @emmamgroarke]

Amazing talk from our @nih_nhlbi fellow @NickLeeMD presenting long-term results from our high-dose Danazol protocol for patients with #TBD. #ASH24 @ASH_hematology @NCICCR_MOS @NealSYoung1 @fergutierrezro1 @bhavishap29 @TeamTelomereInc

[Katsuaki Maehara 🇯🇵 @KatsuakiMaehara]

🫁 ADCs for Lung Cancer 🫁

🌟 Currently approved and in development ADCs.

[ASH @ASH_hematology]

#ASH24 is a celebration of everything that makes #hematology extraordinary — breakthroughs and transformative data are shared amid moments of laughter and connection. 🩸✨

We can't wait to see what day 2 has in store!

[Ruah Alyamany | روى اليماني @Ruah_Mahmoud]

The beauty and complexity of ITP in a slide 😍

Courtesy of Dr. Michele Lambert

#ASH24 #ClassicalHematology

[Emma M. Groarke @emmamgroarke]

Check out our former @nih_nhlbi fellow (now at @UMiamiHealth!) @1JibranDurrani ‘s #ASH24 poster looking at more selective JAKi in our immune BMF model. @bhavishap29 @NealSYoung1 @ASH_hematology #BMFsm

[Sylvester Comprehensive Cancer Center @SylvesterCancer]

. @MikkaelSekeres: I interviewed @ASH_hematology incoming VP, Cindy Dunbar (@cedunbar80) for ASH News TV! We discussed the highly anticipated plenary sessions at #ASH24. Stay tuned for more. 🤳🏼

[Rafael Fonseca MD 🦔🇺🇸🏜🇲🇽 @Rfonsi1]

Discontinuation of len maintenance based on MRD status. Most treated with triplets.A bit enriched for lower risk cases (by definition by being sustained MRD-)
#ASH24RF #MMSM

[Emma M. Groarke @emmamgroarke]

Stop by the oral #IBMFS session happening now in Room 11! Moderated by my colleague @fergutierrezro1 @nih_nhlbi and Madhavi Lakkaraja. #ASH24 @ASH_hematology

[Bhavisha Patel @bhavishap29]

Exciting new study underway for immune BMF including AA, LGL and hypoMDS using ruxolitinib @nih_nhlbi led by my colleague @emmamgroarke

[Dr. David J. Young, MD PhD @DrDavidJYoung]

Speaking of variant detection: an elegant talk by @st_esquius showing that up to a *third of patients* (!) have P/LP germline variants, with the presence of symptoms/signs having a high PPV for finding something. #TestingMatters

#ASH24 #HemeTwitter